advertisement
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Delve into the cutting-edge advancements presented at ACC 2025 in Chicago through these focused video briefs from leading cardiologists as they dissect the latest clinical trial data surrounding emerging non-steroidal mineralocorticoid receptor antagonist therapy.
3
1-4 of 4
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Finnian R. McCausland, MD
- DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Albuminuria Change and Finerenone's Effect on CV Outcomes
Finnian R. McCausland, MD
- DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
The CONFIDENCE Trial: Data Insights
prof. Hiddo Heerspink
- DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Topline Results of the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU